Philip Morris stock rises on FDA's first nicotine pouch approval
Shares of Philip Morris International Inc. (NYSE:PM) rose 1% following the U.S. Food and Drug Administration's (FDA) ...
FDA Finally Revokes FD&C Red No. 3 For Food And Drugs
The FDA revokes FD&C Red No. 3 authorization due to cancer concerns under the Delaney Clause, impacting food and drug ...
MedPage Today56m
HHS Inspector General Raises Concerns Over FDA's Accelerated Approvals
Of the 24 drugs, three approvals deviated from the others -- aducanumab; the synthetic hormone hydroxyprogesterone caproate ...
FDA OKs sales of Zyn nicotine pouches, citing health benefits for adult smokers
Federal health officials are backing the health benefits of nicotine pouches, ruling that Philip Morris International’s Zyn ...
ImmunityBio Shares Climb After Company Previews FY25 Regulatory Advances
ImmunityBio also said it will submit a regulatory filing for an alternative source of Bacillus Calmette-Guerin, a drug which treats bladder cancer. The company expects to produce large quantities of ...
BioSpace1h
Manufacturing Issues Result in FDA Rejection of Atara’s Cell Therapy
Atara Therapeutics’ Ebvallo, already marketed in Europe for a transplant-related blood cancer, will not hit the U.S. market ...
FDA Approves Zyn Pouches For Sale As Less Harmful Alternative To Cigarettes
The increasingly popular nicotine pouches pose a lower risk of cancer than cigarettes, U.S. health officials said.
How Can Health Care Startups Cut Through Wellness Misinformation? This Company Has a Plan
With $10 million in new funding, Teal Health co-founder Kara Egan shares how her cervical cancer testing startup intends to reach its first patients.
Philip Morris Shares Advance 1% After FDA Authorizes Marketing of Zyn
Philip Morris International shares edged up slightly after the Food and Drug Administration authorized marketing for 20 Zyn nicotine-pouch products. The stock rose about 1%, to $119.40, late Thursday ...
Healio2h
IBD drug market rattles as Lilly’s Omvoh nabs FDA approval for second IL-23p19 in Crohn’s
The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second interleukin-23p19 specific inhibitor approved for both major types of inflammatory ...